Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update

Go back to Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update

Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q

May 9, 2018 8:01 AM EDT

Cantor Fitzgerald reiterated an Overweight rating and $22.00 price target on Ocular Therapeutix (NASDAQ: OCUL) following the company's 1Q earnings report. Management reported a 1Q18 year-end cash and equivalents balance of $63 million, which analyst Elemer Piros believes provides a cash runway beyond a... More